The clinical implication of these results is far-reaching, not only because NPM1-mutated AML represents the largest uniform subgroup within AML but also because these patients are classified as being of standard risk, for whom the best treatment strategy (transplantation versus chemotherapy) in unclear. The gene discussed is NPM1; the disease is acute myeloid leukemia.